Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
复制标题
DOI：
10.1038/sj.bjc.6603477
复制
发表时间：
2006-12-04
影响因子：
8.8
通讯作者：
Kikkawa, F
中科院分区：
文献类型：
--
作者：
Ino, K;Yoshida, N;Kajiyama, H;Shibata, K;Yamamoto, E;Kidokoro, K;Takahashi, N;Terauchi, M;Nawa, A;Nomura, S;Nagasaka, T;Takikawa, O;Kikkawa, F
吲哚胺2，3-双加氧酶（Indoleamine 2，3-dioxygenase，IDO）是一种诱导免疫耐受的色氨酸分解酶。本研究旨在探讨IDO在子宫内膜癌中的表达及其预后意义。将子宫内膜癌组织（n=80）中吲哚胺2，3-双加氧酶的表达进行化学评分，分为4组（IDO−、1+、2+和3+）。IDO高表达（IDO 2+或3+）37例（46.3%），与手术分期、肌层浸润、淋巴管间隙受累、淋巴结转移呈正相关，而与组织学分级无关。与IDO无表达或弱表达（IDO-或1+）的患者相比，IDO高表达患者的总生存期和无进展生存期（PFS）显著受损（分别为P=0.002和P=0.001）。IDO−/1+、2+和3+的5年PFS分别为97.7%、72.9%和36.4%。即使在早期疾病患者中（国际妇产科联盟I/II，n=64），IDO 2 +/3+的PFS也显著低于IDO−/1+（P=0.001）。多因素分析显示，IDO表达是PFS的独立预后因素（P=0.020）。这些结果表明，IDO高表达参与子宫内膜癌的进展，并与受损的临床结果相关，提示IDO是一种新的和可靠的子宫内膜癌预后指标。
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in endometrial cancer tissues (n=80) was immunohistochemically scored as four groups (IDO−, 1+, 2+, and 3+). The high IDO expression (IDO2+ or 3+) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade. Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P=0.002 and P=0.001, respectively) compared to patients with no or weak expression of IDO (IDO− or 1+). The 5-year PFS for IDO−/1+, 2+, and 3+ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n=64), the PFS for IDO2+/3+ was significantly poor (P=0.001) compared to that for IDO−/1+. On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P=0.020). These results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.